Crofab Injection, Powder, Lyophilized, For Solution
Product Images NDC 50633-110

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Crofab (NDC 50633-110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Btg International Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Crofab 01)

Figure1 (Crofab 01)
This document appears to be a medical record or chart for a patient. It includes data on "platelets," which were measured at "107/mm" and the document also shows a graph that measures something over the course of several hours. There is some information about different patients, including their age and the medication they are taking. However, there is not enough context to determine the purpose of the data or the condition of the patient.*
FDA Label Image

Figure2 (Crofab 02)

FDA Label Image

Vial-label (Crofab 03)

FDA Label Image

Carton-label (Crofab 04)

Carton-label (Crofab 04)
CroFab® is a medication used for the treatment of venomous snake bites. It is an immune fab (fragment antigen-binding) containing a mixture of purified antibody fragments derived from the blood of sheep that have been immunized with the venom of four different species of snakes. Each vial of CroFab® contains antibodies against 18 mL of venom. The package consists of two vials that need to be reconstituted with 0.9% normal saline. The selection of mice used to test the potency has been changed; therefore, the minimum lethal dose of the venom-neutralizing units has been altered, but it does not reflect any change in the product's potency. CroFab® is a registered trademark of BTG International and distributed by BTG. The medication must be used immediately after reconstitution and stored between 2-8°C (36-46°F). It is essential not to shake the medication, and diluent is not included in the package.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.